1.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2105, NCT00303251
|
|
2.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: LCCC 2010-535, NCT01484041
|
|
3.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2201, 2008-005870-11, NCT00790426
|
|
4.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2204, 2009-012417-22, NCT01058434
|
|
5.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SOGUG2011-03, 2011-002873-47, NCT01514526
|
|
6.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2106, NCT00669097
|
|
7.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2107, 2007-004391-39, NCT00715182
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2112, NCT01030055
|
|
9.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2116, NCT01155713
|